# Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

> **NCT00663260** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 631 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00663260
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-12
- **Final completion:** 2011-06
- **Target enrollment:** 631 (ACTUAL)
- **Last updated:** 2017-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00663260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00663260, "Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00663260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*